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Abstract
Pancreatitis is a significant clinical problem and the lack of effective therapeutic options means that treatment
is often palliative rather than curative. A deeper understanding of the pathogenesis of both acute and chronic
pancreatitis is necessary to develop new therapies. Pathological changes in pancreatitis are dependent on innate
immune cell recruitment to the site of initial tissue damage, and on the coordination of downstream inflammatory
pathways. The chemokine receptor CXCR2 drives neutrophil recruitment during inflammation, and to investigate
its role in pancreatic inflammation, we induced acute and chronic pancreatitis in wild-type and Cxcr2−/− mice.
Strikingly, Cxcr2−/− mice were strongly protected from tissue damage in models of acute pancreatitis, and this
could be recapitulated by neutrophil depletion or by the specific deletion of Cxcr2 from myeloid cells. The pancreata
of Cxcr2−/− mice were also substantially protected from damage during chronic pancreatitis. Neutrophil depletion
was less effective in this model, suggesting that CXCR2 on non-neutrophils contributes to the development of
chronic pancreatitis. Importantly, pharmacological inhibition of CXCR2 in wild-type mice replicated the protection
seen in Cxcr2−/− mice in acute and chronic models of pancreatitis. Moreover, acute pancreatic inflammation was
reversible by inhibition of CXCR2. Thus, CXCR2 is critically involved in the development of acute and chronic
pancreatitis in mice, and its inhibition or loss protects against pancreatic damage. CXCR2 may therefore be a
viable therapeutic target in the treatment of pancreatitis.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Pancreatitis is a source of significant morbidity and mor-
tality. However, the lack of effective interventionsmeans
the emphasis in clinical practice is on supportive care
or prevention, rather than cure, and an improved under-
standing of the pathogenesis of pancreatic inflamma-
tion is required to develop new strategies for therapeutic
intervention [1].
Acute pancreatitis arises as a result of damage to
acinar cells. In humans, this is most often caused by
excess alcohol intake or biliary blockade, which can
be mimicked in mice by injection of the cholecys-
tokinin analogue caerulein. Trypsinogen activation
accounts for some of the pancreatic damage that
develops in acute pancreatitis [2], but tissue dam-
age is substantially augmented by the inflammatory
response [3,4]. The transcription factors NF-κB [3],
AP-1, and NFAT [5,6] are also activated and induce the
production of pro-inflammatory mediators including
CXC chemokines (eg CXCL1 [7] and CXCL2 [8]),
CC chemokines (including CCL2 [9]), and cytokines
such as interleukin (IL)-6 [10], TNFα [11], and IL-1β.
These mediators drive an acute inflammatory response
characterized by the influx of innate immune cells, first
neutrophils and then monocytes, to the site of damage.
Deletion of IL-1β and TNF reduces the severity of acute
pancreatitis [11], while TLR4 deletion reduces innate
immune cell recruitment to the pancreas, possibly by
suppressing CXCL2 production [12]. The infiltrating
leukocytes augment acinar cell damage and intra-acinar
cell trypsinogen activation [13], and the release of
reactive oxygen species or proteases may have a key
role in these processes [13–15]. In most cases, acute
pancreatitis resolves with tissue repair and regeneration,
but in severe cases a cycle of damage and inflammation
is set in motion whereby pro-inflammatory cytokines
act systemically and, unless reversed, result in systemic
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inflammatory response syndrome and potentially organ
failure and death.
The pathogenesis of chronic pancreatitis is less
well understood [5]. Current thinking asserts that it
is a ‘two-hit’ phenomenon in which initial damage
generates acute pancreatitis and a second ‘hit’ drives
progression to chronic pancreatitis. This second hit
reprogrammes the acute inflammatory response to pro-
mote chronic inflammation, stellate cell activation, and
fibrosis, thus instigating a necrosis/fibrosis cycle that
is perpetuated by recurrent acute attacks [16]. Effective
therapies must therefore allow healing and regeneration
after acute pancreatitis and before fibrosis and chronic
pancreatitis develop.
Due to their key role in inflammation, neutrophils are
considered a potential therapeutic target in acute pan-
creatitis. The chemokine receptor CXCR2 is known to
make a major contribution to neutrophil migration in
vivo. In humans, CXCR2 acts as a receptor for seven
different chemokines (CXCL1–3 and CXCL5–8), two
of which (CXCL6 and CXCL8) also signal through the
closely related receptor CXCR1 [17]. Mice lack CXCL8
(previously known as IL-8) and only a single orthologue
exists for CXCL5 and CXCL6, so CXCR2 only has five
chemokine ligands in mice, although non-chemokine
ligands have also been reported to activate this receptor
[18,19]. Whilst CXCR2 has been implicated in a diverse
range of cellular processes, such as development [20],
angiogenesis [21], senescence [22], and tumour cell pro-
liferation and invasion [23], it is best known for its abil-
ity to control leukocyte migration. It plays a particularly
prominent role in directing neutrophil migration, includ-
ing release from the bone marrow and recruitment into
inflamed tissues [24,25]. However, functional CXCR2
expression has also been reported on other leukocytes,
including T-lymphocytes, NK cells, and monocytes in
humans [26–29], and monocytes in mice [30–32].
Here, using genetically modified mice, we show that
CXCR2 is critical for the recruitment of neutrophils into
the pancreas in models of acute and chronic pancreatitis,
and that this plays a key role in driving the acinar cell
damage seen in these models. Moreover, a CXCR2
inhibiting peptide, ‘pepducin’, protects wild-type mice
against acute and chronic pancreatitis and, significantly,
can reverse established pancreatic inflammation. Thus,
inhibitors of CXCR2 signalling could be of benefit in
the treatment of both acute and chronic pancreatitis in
humans.
Materials and methods
Mice
Animals of BALB/c (all Cxcr2−/− and controls) or
C57Bl/6 (all Cxcr2fl/fl mice and controls) background
were maintained in conventional animal facilities and
monitored daily. Experiments were carried out in com-
pliance with UK Home Office guidelines under licence
and approved by the local ethical review committee.
Wild-type animals were purchased from Charles River
Laboratories (Margate, Kent, UK). Cxcr2−/− mice were
obtained from Jackson Laboratories (Maine, USA),
and genotyped by Transnetyx (Cordova, TN, USA).
As Cxcr2−/− mice can be smaller than average, we
used only mice of a comparable size to controls for all
experiments.
Experimental pancreatitis
Acute pancreatitis was induced by intraperitoneal
(i.p.) injection of 0.2mg/kg caerulein (Sigma Aldrich,
St Louis, MO, USA) every hour for 6 h. Animals were
sacrificed 1 or 18 h after the final injection. Chronic
pancreatic inflammation was induced by i.p. injection
of 0.2mg/kg caerulein once daily for a continuing cycle
of 5 days on, 2 days off. Animals were aged to 6 weeks
or 9 months. Groups of five age-matched wild-type and
Cxcr2−/− mice were used.
Treatment studies
Healthy, age-matched mice were randomly assigned
to control or treatment in each case and treated and
assessed at the same time. Further details may be found
in the Supplementary materials and methods.
Assessment of circulating cells
Blood was obtained post mortem from mice by cardiac
puncture, collected into EDTA-coated tubes, and anal-
ysed immediately using an ADVIA2120 Haematology
system (Siemens, Munich, Germany) by the University
of Glasgow Veterinary Diagnostics Service.
Human pancreatic tissue
Tissue from pancreata resected from human patients
with pancreatitis was obtained from Glasgow Biorepos-
itory. Expression was assessed by immunohistochem-
istry.
Immunohistochemistry
Sections were stained using standard immunohisto-
chemistry protocols. Further details may be found in the
Supplementary materials and methods.
Flow cytometry
Flow cytometry was performed using standard proto-
cols. Further details may be found in the Supplementary
materials and methods.
Results
CXCR2 drives acute pancreatic inflammation
and acinar damage
To assess the role of CXCR2 in the pathogenesis of acute
pancreatitis, we compared the responses of Cxcr2−/−
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Figure 1. Cxcr2 deletion protects the pancreas from the effects of acute pancreatitis. (A) Schematic diagram of induction of acute
pancreatitis, showing the frequency of caerulein injections and sampling time-points. (B) H&E staining of pancreata from WT (left) and
Cxcr2−/− (right) mice 1 h after induction of acute pancreatitis. (C–E) Boxplots showing quantification of (C) acinar damage (p< 0.05,
Mann–Whitney, n= 4), (D) MPO+ neutrophils (p< 0.02, Mann–Whitney, n= 4), and (E) cleaved caspase 3 (p= 0.139, Mann–Whitney,
n= 4) in WT and Cxcr2−/− mice 1 h after induction of acute pancreatitis. (F) H&E staining of pancreata from WT (left) and Cxcr2−/− (right)
mice 24 h after induction of acute pancreatitis. (G–I) Boxplots showing quantification of (G) acinar damage (p< 0.05, Mann–Whitney,
n= 4), (H) MPO+ neutrophils (p< 0.05, Mann–Whitney, n= 4 mice), and (I) cleaved caspase 3 (p= 0.289, Mann–Whitney, n= 4) in WT
and Cxcr2−/− mice 24 h after induction of acute pancreatitis. (J) IHC for cleaved caspase 3 in pancreata from WT (left) and Cxcr2−/− (right)
mice 24 h after induction of acute pancreatitis. (K) IHC for MPO to detect neutrophils infiltrating the pancreas 24 h after induction of acute
pancreatitis. (L) CXCR2 staining 24 h after induction of acute pancreatitis. Arrows indicate positive cells. (M, N) FACS analysis confirms the
decrease in recruitment of (M) CD11b+ Ly6G+ neutrophils (quantified on right, n≥ 3) and (N) CD11b+ F4/80+ monocytes (quantified on
right, n≥ 3) to the pancreas of Cxcr2−/− mice 24 h after induction of acute pancreatitis.
mice [24] and age-matched wild-type mice to repeated
treatment with caerulein [33]. A series of seven hourly
injections of caerulein results in a condition that mim-
ics the pathology of human acute pancreatitis [34]
(Figure 1A).
Mice were sacrificed 1 h after the final injection
of caerulein, after the first peak of trypsin activity in
this model [35,36]. From inspection of H&E-stained
sections, it was clear that acute pancreatic damage
had been induced by the caerulein in wild-type and
Cxcr2−/− pancreata, and apoptotic figures and inflam-
matory cells were evident (Figure 1B). Acinar damage
was assessed using a standard scoring system based
on morphometry [2] (Figure 1C). Immunohistochem-
istry (IHC) showed that the immune cell infiltrate at this
time-point consisted predominantly of myeloperoxidase
(MPO)-positive neutrophils, and these cells were sub-
stantially reduced in Cxcr2−/− pancreata (Figure 1D).
Apoptotic cells were quantified by IHC for cleaved
caspase 3, but no significant difference was observed
between groups (Figure 1E), suggesting that the damage
sustained from caerulein-induced pancreatic enzyme
stimulation was not substantially affected by CXCR2
deficiency. Interestingly, despite containing similar
numbers of apoptotic cells, the pancreata of Cxcr2−/−
mice exhibited significantly reduced levels of acinar
damage compared with wild-type mice.
To determine the contribution of CXCR2 to sec-
ondary inflammation and damage in acute pancreatitis,
wild-type and Cxcr2−/− mice were administered seven
hourly injections of caerulein and sacrificed 24 h after
the first injection (Figure 1A). At this time, inflam-
matory infiltrates, oedema, and necrosis are present
in the pancreas [34]. Wild-type pancreata were visi-
bly oedematous compared with Cxcr2−/− pancreata.
H&E staining revealed tissue oedema and leukocyte
infiltrates in wild-type pancreata that were not seen
in their Cxcr2−/− counterparts (Figure 1F). When
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Figure 2. CXCR2 expression on myeloid cells determines damage in acute pancreatitis. (A) PCR of DNA from wild-type mice and mice
heterozygous for the Cxcr2fl/fl allele. (B) H&E staining demonstrating significant pancreatic damage in LysMCre, Cxcr2+/+ mice (left)
compared with LysMCre, Cxcr2fl/fl mice (right), 24 h following induction of acute pancreatitis. (C) Boxplot showing quantification of acinar
damage as a percentage of total acinar tissue per× 200 field of view. p< 0.05, Mann–Whitney, n= 3 mice. (D) Immunohistochemistry
for MPO, demonstrating MPO+ neutrophil infiltrate in LysMCre, Cxcr2+/+ mice (left) compared with LysMCre, Cxcr2fl/fl mice (right), 24 h
following induction of acute pancreatitis. (E) Boxplot showing quantification of MPO+ neutrophils. Note the significantly fewer MPO+
neutrophils within the pancreas of LysMCre, Cxcr2fl/fl mice compared with LysMCre, Cxcr2+l+ mice. Black arrow denotes neutrophil infiltrate.
p <0.05, Mann–Whitney, n= 3 mice.
acinar damage was quantified, it was found to be
approximately five-fold higher in the pancreata of
wild-type mice than in Cxcr2−/− animals (Figure 1G).
Similar to the 1 h time-point, no significant difference
was observed in the number of apoptotic cells between
groups (Figure 1I), as quantified by IHC for cleaved
caspase 3 (Figure 1J). IHC confirmed that the immune
cell infiltrate consisted predominantly of MPO-positive
neutrophils at this time-point (Figure 1K), and these
cells were substantially reduced in Cxcr2−/− pancreata
(Figure 1H). As expected, cells within the infiltrate of
wild-type pancreata expressed CXCR2 (Figure 1L).
Presence of macrophages was assessed at both 1-h and
24-h time-points in wild-type mice, and while very few
macrophages were seen at 1 h after pancreatitis induc-
tion, high numbers were seen at the 24-h time-point
(Supplementary Figure 1A). Very few CD3-positive T
cells were present in the pancreata of either wild-type
or Cxcr2−/− mice (Supplementary Figure 1B). We also
analysed cells isolated from the pancreata of wild-type
and Cxcr2−/− mice by flow cytometry and found that in
keeping with our immunohistochemical data, the num-
bers of CD11b+Ly6G+ and CD11b+F4/80+ cells were
reduced in pancreata following pancreatitis induction
(Figures 1M and 1N and Supplementary Figure 2).
Collectively, these data show that CXCR2 defi-
ciency prevents leukocyte recruitment into the
pancreas and protects the pancreatic parenchyma
from inflammation-induced damage. Importantly, this
reduction in recruitment into the pancreas is not due to
a lack of circulating neutrophils in Cxcr2−/− mice, as
shown by full blood counts from these mice (Supple-
mentary Figure 3). Interestingly, although circulating
leukocyte levels are higher in Cxcr2−/− mice, due to
failed homing of the neutrophils, under inflammatory
conditions this appears to be corrected.
Deletion of Cxcr2 from myeloid cells is sufficient
for protection from acute pancreatitis
In inflamed wild-type pancreata, CXCR2 expression is
restricted to infiltrating leukocytes (Figure 1L). In order
to determine whether the protection offered by Cxcr2
deletion was a result of loss of CXCR2 from myeloid
cells, we developed a conditional floxed allele of Cxcr2
(Figure 2A). To specifically delete CXCR2 in myeloid
cells, we crossed thesemicewith animals expressingCre
recombinase under the control of the lysozyme M pro-
moter (LysMCre) [37]. Acute pancreatitis was induced
in cohorts of LysMCre, Cxcr2+/+ and LysMCre, Cxcr2fl/fl
mice, and as above, animals were analysed 24 h after the
first caerulein injection. We observed a striking level of
pancreatic parenchymal damage in LysMCre, Cxcr2+/+
mice as expected. In contrast, LysMCre, Cxcr2fl/fl mice
were completely protected (Figures 2B and 2C). In
addition, MPO+ neutrophils were virtually absent from
the pancreata of LysMCre, Cxcr2fl/fl mice compared
with LysMCre, Cxcr2+/+ controls (Figures 2D and 2E).
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Importantly, Pdx1-Cre, Cxcr2fl/fl mice, in which Cxcr2
is deleted from pancreatic epithelial cells, were not
protected from pancreatitis (Supplementary Figure 4).
Thus, CXCR2 deficiency inmyeloid cells interferes with
neutrophil recruitment to the pancreas and protects the
pancreas from inflammation.
Neutrophil depletion and CXCR2 inhibition protect
against acute pancreatitis
Neutrophils are by far the most dominant source of
CXCR2 in mice, and the phenotypes in Cxcr2−/− mice
are likely to be due to loss of CXCR2 from neu-
trophils. The results predict that neutrophil depletion or
the pharmacological targeting of CXCR2 should protect
wild-type mice from acinar cell damage and pancreatic
inflammation. To examine this, we used anti-Ly6Gmon-
oclonal antibody (1A8) to deplete Ly6G+ neutrophils
and a CXCR2 targeting peptide ‘pepducin’ that inter-
feres with the intracellular coupling of the G-protein
loops of CXCR2 to prevent CXCR2 signalling [19].
First, we assessed whether prophylactic treatment
with pepducin or anti-Ly6G antibody could protect
against acute pancreatitis. Wild-type mice were dosed
with pepducin, anti-Ly6G antibody or control 24 h and
1 h before inducing acute pancreatitis (Figure 3A).
Animals were sacrificed 24 h after induction of acute
pancreatitis. We confirmed that anti-Ly6G reduced the
circulating neutrophil counts significantly compared
with control mice (Figure 3B). While there was no
significant difference between control and CXCR2
pepducin-treated animals, there was a trend towards
higher numbers of circulating neutrophils in CXCR2
pepducin-treated mice, perhaps due to reduced homing
to the pancreas. As expected, pancreata from control
mice showed evidence of tissue damage, apoptotic
bodies within acinar cells, and infiltration by inflam-
matory cells (Figures 3C, 3E, and 3G). In contrast, the
pancreata of wild-type mice treated with pepducin or
anti-Ly6G showed a significant reduction in acinar cell
damage (Figures 3C and 3D) and were virtually devoid
of MPO+ neutrophils (Figures 3E and 3F). As with
CXCR2 deficiency, the treatment of wild-type mice
with pepducin or anti-Ly6G resulted in a substantial
reduction in the number of F4/80+ macrophages present
in the pancreas 24 h after the first caerulein injection
(Figures 3G and 3H).
Taken together, the data suggest that inhibition of neu-
trophil infiltration to the pancreas, either by Cxcr2 dele-
tion, CXCR2 inhibition or neutrophil depletion, restricts
pancreatic damage in response to caerulein-induced
acute pancreatitis and prevents the development of a
pancreatic monocyte–macrophage infiltrate.
CXCR2 inhibition ameliorates tissue damage
in mice with ongoing acute pancreatitis
Next, in order to assess the potential therapeutic util-
ity of CXCR2 inhibition in acute pancreatitis, we
investigated whether inhibition of CXCR2 or neutrophil
ablation could reverse or dampen ongoing pancreatic
inflammation. As before, we induced acute pancre-
atitis in wild-type mice by seven hourly injections of
caerulein, but this time we treated with CXCR2 pep-
ducin, anti-Ly6G antibody or control 1 h after the final
injection (Figure 4A). At this time in this model, the
trypsin activity has already peaked [2] and substantial
chemical and inflammation-induced damage is apparent
in the pancreas (Figure 1). Animals were sacrificed
24 h after pepducin or anti-Ly6G treatment. H&E stain-
ing revealed greater immune cell infiltrate and tissue
damage in control animals compared with CXCR2
pepducin-treated or anti-Ly6G antibody-treated mice
(Figure 4B). Upon quantitation, it was clear that acinar
damage was not reduced to the low levels observed
in the prevention experiment (Figure 3), but, nonethe-
less, treatment with pepducin or anti-Ly6G was able
to prevent tissue damage caused by ongoing acute
pancreatitis (Figure 4C). As in previous experiments,
both CXCR2 inhibition and neutrophil ablation in this
context significantly reduced the number of neutrophils
(Figures 4D and 4E) and macrophages (Figures 4F and
4G) in the pancreata.
Importantly, these data show that blocking CXCR2 or
depleting neutrophils can significantly reduce pancreatic
damage, even when it is initiated after the onset of acute
pancreatitis. CXCR2 may therefore have considerable
potential as a therapeutic target in the treatment of acute
pancreatitis.
CXCR2 deletion protects against the effects
of recurrent acute pancreatic damage
Chronic pancreatitis is a multifactorial disease that
often arises in response to recurrent bouts of acute,
often subclinical, pancreatitis. Recurrent inflam-
mation generates a cycle of leukocyte infiltration
(particularly neutrophils and monocytes), stellate cell
activation [by macrophage-derived cytokines including
platelet-derived growth factor and transforming growth
factor beta (TGFβ)], and fibrotic tissue deposition. To
investigate whether CXCR2 might play a role in this
process, we wanted to examine the role of CXCR2 in a
mouse model of chronic pancreatitis. Chronic pancre-
atitis is most often induced over a period of 6 weeks
via recurrent acute pancreatitis twice weekly [38].
However, this model represents a significant necrotic
insult to the pancreas and relies on extensive damage
and repair. We therefore decided to generate chronic
pancreatitis in mice using a low-grade regimen of recur-
rent intra-peritoneal caerulein injections five days per
week for 6 weeks [39]. When sacrificed at the 6-week
time-point, wild-type pancreata had significant inflam-
matory infiltrate and tissue damage (Figure 5A, left),
but no evidence of fibrosis. In contrast, the pancreata
of Cxcr2−/− mice were almost devoid of inflammatory
cells (Figure 5A, right) and virtually no apoptotic cells
were present (Figure 5B). MPO+ cells and F4/80+
macrophages were present in wild-type pancreata but
were barely detectable inCxcr2−/− mice (Figures 5C, 5D
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Figure 3. CXCR2 inhibition protects the pancreas from the effects of acute pancreatitis. (A) Schematic diagram of induction of acute
pancreatitis, showing timing of treatment, frequency of caerulein injections, and sampling time-points. (B) Boxplot showing quantification
of circulating blood neutrophils compared between treatment groups. Control versus CXCR2 pepducin, p= 0.121. Control versus anti-Ly6G,
p< 0.05, Mann–Whitney n= 5 mice in each group. (C) H&E staining of pancreata from vehicle-treated (left), CXCR2 pepducin-treated
(middle), and anti-Ly6G-treated (right) wild-type mice 24 h following induction of acute pancreatitis. (D) Boxplot showing quantification
of acinar damage compared between treatment groups. Control versus CXCR2 pepducin, p< 0.05. Control versus anti-Ly6G, p< 0.05,
Mann–Whitney, n= 5 mice in each group. (E) Immunohistochemistry for MPO to detect neutrophils in pancreata from vehicle-treated
(left), CXCR2 pepducin-treated (middle), and anti-Ly6G-treated (right) wild-type mice 24 h after induction of acute pancreatitis. (F) Boxplot
showing quantification of MPO+ neutrophils compared between treatment groups. Control versus CXCR2 pepducin, p< 0.05. Control
versus anti-Ly6G, p< 0.05, Mann–Whitney, n= 5 mice in each group. (G) Immunohistochemistry for F4/80 to detect macrophages in
pancreata from vehicle-treated (left), CXCR2 pepducin-treated (middle), and anti-Ly6G-treated (right) wild-type mice 24 h after induction
of acute pancreatitis. (H) Boxplot showing quantification of F4/80+ macrophages compared between treatment groups. Control versus
CXCR2 pepducin, p< 0.05. Control versus anti-Ly6G, p< 0.05, Mann–Whitney, n= 5 mice in each group.
and 5F, 5G). These data were confirmed by flow cytom-
etry (Figures 5E and 5H–5J). Full blood counts
again showed that the lack of neutrophils recruited
to the pancreata of Cxcr2−/− mice is not due to low
numbers of circulating cells (Supplementary Figure
5). Thus, Cxcr2−/− mice appeared to be completely
protected from the effects of low-grade pancreatic
inflammation.
In keeping with this hypothesis, when we stained
pancreata from wild-type and Cxcr2−/− mice 24 h fol-
lowing induction of acute pancreatitis, we found occa-
sional cells positive for nuclear NF-κB-p65, indicative
of NF-κB signalling, in wild-type, but not in Cxcr2−/−
pancreata. After 6 weeks of chronic inflammation, the
number of cells positive for nuclear NF-κB increased
in wild-type pancreata; however, we only observed
cytoplasmic staining in Cxcr2−/− mice (Supplementary
Figure 6).
Cxcr2 deletion protects against many features
of chronic pancreatitis
To model chronic pancreatitis more accurately, we
extended our regime and injected mice i.p. with
caerulein for 9 months, 5 days per week (Figure 6). This
was expected to induce significant fibrosis and tissue
atrophy in the pancreas [39]. In wild-type mice, there
was significant leukocyte infiltration of the pancreas
with resultant tissue damage and extensive atrophy. In
contrast, Cxcr2−/− pancreata had fewer areas of tissue
atrophy and little evidence of leukocyte infiltrate. In
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Figure 4. CXCR2 inhibition following induction of acute pancreatitis rescues the pancreatic parenchymal damage phenotype in a
neutrophil-dependent manner. (A) Schematic diagram of induction of acute pancreatitis, showing timing of treatment, frequency of
caerulein injections, and sampling time-points. (B) H&E staining of pancreata from vehicle-treated (left), CXCR2 pepducin-treated (middle),
and anti-Ly6G-treated (right) wild-type mice 24 h following induction of acute pancreatitis. (C) Boxplot showing quantification of acinar
damage compared between treatment groups. Control versus CXCR2 pepducin, p< 0.05. Control versus anti-Ly6G, p< 0.05, Mann–Whitney,
n= 5 mice in each group. (D) Immunohistochemistry for MPO to detect neutrophils in pancreata from vehicle-treated (left), CXCR2
pepducin-treated (middle), and anti-Ly6G-treated (right) wild-type mice 24 h after induction of acute pancreatitis. (E) Boxplot showing
quantification of MPO+ neutrophils compared between treatment groups. Control versus CXCR2 pepducin, p< 0.05. Control versus
anti-Ly6G, p< 0.05, Mann–Whitney, n= 5 mice in each group. (F) Immunohistochemistry for F4/80 to detect macrophages in pancreata
from vehicle-treated (left), CXCR2 pepducin-treated (middle), and anti-Ly6G-treated (right) wild-type mice 24 h after induction of acute
pancreatitis. (G) Boxplot showing quantification of F4/80+ macrophages compared between treatment groups. Control versus CXCR2
pepducin, p< 0.05. Control versus anti-Ly6G, p< 0.05, Mann–Whitney, n= 5 mice in each group.
wild-type mice, the inflammatory infiltrate consisted
mainly of MPO+ neutrophils and F4/80+ macrophages
(Figures 6B, 6C and 6G, 6H).
We hypothesized that the reduction in macrophages
in the pancreata of Cxcr2−/− mice would have an
effect on stellate cell activation. Stellate cell activa-
tion, assessed by alpha-smooth muscle actin (αSMA)
staining, was indeed decreased in Cxcr2−/− mice com-
pared with wild-type (Figure 6D). In this model of
chronic pancreatitis, we found that fibrotic tissue and
concurrent atrophy accumulated over time (data not
shown). At the 9-month time-point, picrosirius red
staining demonstrated significant pancreatic fibrosis in
wild-type mice (Figure 6E). In some wild-type mice,
however, there was complete atrophy of the gland and
very little fibrosis remaining. Thus, when we quantified
fibrosis, we could not detect a significant difference
between wild-type and Cxcr2−/− mice (Figure 6F).
Taken together, our data show that loss of CXCR2
reduces the number of infiltrating innate immune cells
in chronic pancreatitis, thus protecting the pancre-
atic parenchyma from destruction by neutrophils and
macrophages.
Pharmacological CXCR2 inhibition replicates
the protective effects of Cxcr2 deletion
Next, we tested the therapeutic potential of CXCR2
inhibition in the prevention and treatment of chronic
pancreatitis. We induced chronic pancreatic inflam-
mation in wild-type mice over the course of 6 weeks,
as before (Figure 5), treating them throughout with
CXCR2-inhibiting pepducin, neutrophil-depleting
anti-Ly6G antibody, or vehicle. As before, in the control
group, we observed significant damage to the pancreatic
parenchyma and substantial leukocyte infiltration
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Figure 5. Cxcr2 deletion protects against the effects of recurrent acute pancreatic inflammation. (A) H&E staining of pancreata from
wild-type (left) and Cxcr2−/− (right) mice following 6 weeks of pancreatic inflammation. Red arrow denotes necrotic cell; black arrow
significant immune cell infiltrate. (B) Immunohistochemistry for cleaved caspase 3 to detect apoptotic cells in the pancreas of wild-type (left)
and Cxcr2−/− (middle) mice following 6 weeks of pancreatic inflammation. Right panel: boxplot showing quantification of cleaved caspase
3 staining. p< 0.05, Mann–Whitney, n= 4 mice. (C) Immunohistochemistry for MPO to detect neutrophils infiltrating the pancreas of
wild-type (left) and Cxcr2−/− (right) mice following 6 weeks of pancreatic inflammation. (D) Boxplot showing quantification of MPO-positive
neutrophils in the pancreas of wild-type and Cxcr2−/− mice following 6 weeks of pancreatic inflammation. p< 0.05, Mann–Whitney, n= 3
mice. (E) Immunohistochemistry for F4/80 to detect macrophages in the pancreas of wild-type (left) and Cxcr2−/− (right) mice following 6
weeks of pancreatic inflammation. (F) Boxplot showing quantification of F4/80-positive macrophages in the pancreas of wild-type and
Cxcr2−/−mice following 6 weeks of pancreatic inflammation. p< 0.05, Mann–Whitney, n= 3 mice. (G–J) FACS analysis confirms the
decrease in infiltration of (G) CD11b+ Ly6G+ neutrophils (quantified in I, n≥ 3) and (H) CD11b+ F4/80+ macrophages (quantified in J,
n≥ 3) to the pancreas of Cxcr2−/− mice following 6 weeks of pancreatic inflammation.
(Figures 7A–7E). Treatment with anti-Ly6G antibody
to deplete neutrophils failed to prevent damage to the
pancreas, or modify cell death, as detected by staining
for cleaved caspase 3 (Figures 7F and 7G). Remarkably,
however, even after 6 weeks of recurrent inflammation,
the pancreata of CXCR2 pepducin-treated mice were
significantly protected compared with controls, and
far fewer apoptotic cells were present (Figure 7G).
Pepducin treatment also resulted in reduced infil-
tration of the pancreas by both MPO+ neutrophils
and F4/80+ monocytes (Figures 7B–7E). Anti-Ly6G
antibody-treated mice also displayed fewer neutrophils
in their pancreata (Figures 7B and 7C). However,
the macrophage number was increased, even when
compared with control-treated mice (Figures 7D and
7E). Neutrophil ablation alone is therefore insuffi-
cient to provide the same pancreatic protection as
CXCR2 inhibition, with monocytes infiltrating the
pancreas, causing pancreatic damage. These data sug-
gest that CXCR2 inhibition does indeed protect the
pancreas from chronic pancreatic inflammation, first
through inhibition of neutrophil chemotaxis and second
through neutrophil-independent processes, potentially
disruption of the coordination of the innate immune
response, and interference with monocyte chemotaxis.
Encouragingly, even when treatment started 2 weeks
after induction of pancreatitis, pepducin could ‘res-
cue’ the pancreas from damage (Figure 7H). When
we examined expression of CXCR2 in tissue from
patients with chronic pancreatitis, we found that while
a substantial proportion of the pancreas had been
replaced by fibrotic tissue (Figure 7I), dying acini
were heavily infiltrated with CXCR2-positive cells
(Figure 7J). Given that CXCR2 inhibitors are now
available in the clinic [40,41], we believe that these data
provide support for future CXCR2-based therapeutic
intervention.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 237: 85–97
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
CXCR2 signalling in pancreatitis 93
Figure 6. Chronic pancreatitic changes are mediated by neutrophils and macrophages and are ameliorated by Cxcr2 deletion. (A) H&E
staining demonstrating parenchymal changes after 9 months of pancreatic inflammation in wild-type (left) and Cxcr2−/−mice (right). (B)
MPO immunohistochemistry confirms significant numbers of neutrophils infiltrating the pancreas of wild-type mice (left) compared with
Cxcr2−/− mice (right). (C) F4/80 immunohistochemistry confirms significant numbers of macrophages in the pancreas of wild-type mice (left)
compared with Cxcr2−/− mice (right). (D) αSMA immunohistochemistry demonstrates stellate cell activation after 9 months of pancreatic
inflammation in wild-type (left) and Cxcr2−/− mice (right). (E) Fibrosis in wild-type pancreata demonstrated by picrosirius red staining
for collagen I. (F) Boxplot showing quantification of fibrosis in the pancreata of wild-type and Cxcr2−/− mice. p= 0.65, Mann–Whitney.
(G) Boxplot showing quantification of MPO+ neutrophils in the pancreata of wild-type mice compared with Cxcr2−/− mice. p< 0.001,
Mann–Whitney. (H) Boxplot showing quantification of macrophages in the pancreata of wild-type mice compared with Cxcr2−/−mice.
p< 0.05, Mann–Whitney, n= 3 mice in each group.
Discussion
We have shown here that there is excellent ratio-
nale for the use of CXCR2 inhibitors in pancreatic
inflammation. Many of the known molecular pro-
cesses characterized in acute pancreatitis converge
on CXCR2 signalling and stimulate CXC chemokine
release. Our data demonstrate an important role for
CXCR2 in mediating the innate immune cell response
characteristic of pancreatic inflammation. By exten-
sion of our studies from acute pancreatitis, through
recurrent acute inflammation, to the changes of chronic
pancreatitis, we have demonstrated the importance
of CXCR2-mediated immune cell infiltration to the
propagation of all stages of pancreatic inflammation.
We have confirmed the importance of neutrophils in
the pathogenesis of acute pancreatitis both in its early
stages and 24 h after initiation [14]. CXCR2 deficiency,
resulting from genetic knockout or pharmacological
inhibition, prevented chemotaxis of these cells to the
pancreas, an effect equivalent to neutrophil ablation. We
have also shown, through conditional deletion of Cxcr2
in myeloid cells, that CXCR2 signalling in myeloid
cells is vital for the infiltration of these cells to the
pancreas.
Furthermore, we have shown that CXCR2 signalling
links the progression of persistent acute inflammation to
changes associated with chronic pancreatitis. CXCR2
deficiency, both genetic and pharmacologically medi-
ated, protected against innate immune cell infiltration
and the damage incurred following repeated pancre-
atic inflammation. Prolongation of recurrent acute
inflammation studies to 9 months generates a model
that incorporates inflammation with resultant atrophy
and fibrosis and is pathologically more akin to chronic
pancreatitis. In this context, CXCR2 deficiency once
again protected against innate immune cell infiltration,
with reductions in both neutrophil and macrophage
populations evident. Furthermore, CXCR2 deletion
protected against atrophic changes within the pancreas
when chronic pancreatitis was induced. Human chronic
pancreatitis specimens displayed significant fibrosis
and acinar atrophy. CXCR2 staining was very high in
areas of acinar atrophy and exclusively expressed within
immune cells. Thus, our data support the belief that
chronic pancreatitis arises from recurrent pancreatic
inflammation.
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Figure 7. CXCR2 inhibition, but not neutrophil ablation, protects the pancreas from damage associated with chronic pancreatitis. (A) H&E
staining of pancreata from vehicle-treated (left), CXCR2 pepducin-treated (middle), and anti-Ly6G-treated (right) wild-typemice following 6
weeks of caerulein-induced chronic pancreatitis. (B) Immunohistochemistry for MPO to detect neutrophils in pancreata from vehicle-treated
(left), CXCR2 pepducin-treated (middle), and anti-Ly6G-treated (right) wild-type mice following 6 weeks of caerulein-induced chronic
pancreatitis. (C) Boxplot showing quantification of MPO+ neutrophils compared between treatment groups. Control versus CXCR2 pepducin,
p< 0.001. Control versus anti-Ly6G, p< 0.001, Mann–Whitney, n= 5 mice in each group. (D) Immunohistochemistry for F4/80 to detect
macrophages in pancreata from vehicle-treated (left), CXCR2 pepducin-treated (middle), and anti-Ly6G-treated (right) wild-type mice
following 6 weeks of caerulein-induced chronic pancreatitis. (E) Boxplot showing quantification of F4/80+ macrophages compared between
treatment groups. Control versus CXCR2 pepducin, p< 0.001. Control versus anti-Ly6G, p< 0.001, Mann–Whitney, n= 5mice in each group.
(F) Immunohistochemistry for cleaved caspase 3 to detect apoptotic cells in pancreata from vehicle-treated (left), CXCR2 pepducin-treated
(middle), and anti-Ly6G-treated (right) wild-type mice following 6 weeks of caerulein-induced chronic pancreatitis. (G) Boxplot showing
quantification of cleaved caspase 3 compared between treatment groups. Control versus CXCR2 pepducin, p< 0.05. CXCR2 pepducin versus
anti-Ly6G, p< 0.05, Mann–Whitney, n= 5 mice in each group. (H) Boxplot showing quantification of acinar damage in pancreata from
wild-type mice treated with vehicle or CXCR2 pepducin 2 weeks after starting 6 weeks of caerulein-induced chronic pancreatitis. Control
versus CXCR2 pepducin, p< 0.01. Mann–Whitney, n= 5 mice in each group. (I) H&E staining of a section of pancreas resected from a
patient with chronic pancreatitis. (J) Immunohistochemistry for CXCR2 in the same patient, showing that dying acinar cells are heavily
infiltrated with CXCR2-positive cells.
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Other authors have observed similar effects of inhibit-
ing neutrophils in the context of acute pancreatitis [42].
Indeed, neutrophils have the potential to activate acinar
cell trypsinogen [13], and neutrophil-produced reactive
oxygen species are likely to have a key role in this pro-
cess [14]. Recently, it has been shown that trypsinogen
activation is important only in early acute pancreati-
tis, as trypsinogen-null mice demonstrated similar lev-
els of NF-κB expression to controls in the setting of
AP [2]. NF-κB activation, and not trypsinogen acti-
vation, is now considered the important step in main-
taining the immune response in acute pancreatitis. We
have shown that CXCR2 deficiency can interfere with
NF-κB-dependent progression of acute pancreatitis.
Interestingly, in acute pancreatitis, prevention of neu-
trophil chemotaxis was sufficient to prevent subsequent
monocyte infiltration and thereby protect the pancreas
from the necrotizing effects of these cells. However, we
have shown that in the context of recurrent acute inflam-
mation, CXCR2 has effects over and above inhibiting
neutrophils alone, as CXCR2 inhibition prevented
monocyte infiltration that in control and neutrophil
ablated models led to tissue damage and necrosis. Thus,
CXCR2 may be expressed by macrophages in chronic
inflammatory settings, as has been shown previously
in atherosclerosis [43], or perhaps in the absence of
neutrophils, stimulus for monocyte infiltration comes
from an innate mechanism stimulated by neutrophils
[44]. Indeed, we cannot rule out the possibility that
upon neutrophil infiltration, those few tissue-resident
macrophages present play a role in mediating the
chronic effects. CXCR2 knockout protected against
atrophic changes within the pancreas when chronic
pancreatitis was induced. Thus, CXCR2 deficiency
protects pancreatic parenchyma in a fashion dependent
on neutrophil and subsequent monocyte infiltration,
although interestingly, Cxcr2 deletion does appear to
prevent stellate cell activation.
There is some degree of fibrosis in Cxcr2−/− pancre-
ata, which may be explained in different ways. Cxcr2
loss fails to block infiltration of all monocytes to the pan-
creas and those that do reach the pancreas may be suffi-
ciently able to activate stellate cells. Given the very small
numbers of macrophages within the pancreas, however,
this seems unlikely. Stellate cells may also be activated
by cytokines released in an autocrine fashion in response
to damage [45], or become activated in response to
oxidative stress experienced by the pancreas following
repeated caerulein injections [46].
Clinically relevant inhibitors of CXCR2 are now
available for trial in patients [40,41]. We demonstrated
the ability of CXCR2 inhibition to interfere in the
necrotic process of acute pancreatitis, suggesting the
potential for therapeutic trial in both acute and chronic
pancreatitis. Although further work is required to assess
redundancy between CXCR1 and CXCR2 in humans,
dual inhibitors such as reparixin are also available for
use in the clinic [47]. Many patients are at risk of recur-
rent pancreatic inflammation, with no clear aetiology
being diagnosed in 10–30% of cases of acute recur-
rent pancreatitis [48]. The clear association between
CXCR2-positive cells and acinar collapse observed in
human chronic pancreatitis suggests that CXCR2 may
be a powerful therapeutic target in these patients.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Supplementary materials and methods.
Figure S1. Immune cell infiltration in Cxcr2WT mice compared with Cxcr2−/− mice.
Figure S2. Very few immune cells infiltrate the pancreas in untreated mice.
Figure S3. Full blood counts (FBCs) performed on blood from Cxcr2WT and Cxcr2−/− mice, and under control and acute inflammatory conditions.
Figure S4. Pancreas-specific CXCR2 deletion does not protect from pancreatitic inflammation.
Figure S5. Full blood counts (FBCs) performed on blood from Cxcr2WT and Cxcr2−/− mice, and under control and chronic inflammatory conditions.
Figure S6. Activation of NF-κB signalling in both acute and chronic pancreatitis.
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